Dr. Hartmut J. Ehrlich
11 Nov - 2PM to 3:30PM
Auditorium Level 1
Physician and entrepreneur with 30+ years in the bio-pharmaceutical industry, having lived and worked in the US, The Netherlands, Germany, Switzerland, Austria and France.
Since 2013, CEO of Paris-based ABIVAX, which is targeting the immune system to develop novel treatments for inflammatory and viral diseases as well as cancer. Following exciting Phase 2a clinical results in ulcerative colitis (UC) in Sep. 2018, the company focusses on driving its lead compound ABX464 into Phase 2b clinical trials in UC and HIV, as well as clinically exploring additional inflammatory indications (e.g. Crohn’s disease, rheumatoid arthritis, multiple sclerosis).